Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease

Area of Science:

• Pharmacogenomics
• Cardiovascular Medicine
• Drug Metabolism

Background:

• Clopidogrel, a thienopyridine antiplatelet, prevents vascular events but shows significant interpatient variability.
• Variability in forming clopidogrel's active metabolite is a key factor.
• CYP2C19 and P-glycoprotein genetic variations frequently impact drug efficacy.

Purpose of the Study:

• To investigate the clinical significance of CYP2C19 and P-glycoprotein alleles in clopidogrel therapy.
• To evaluate the utility of identifying patients with high-risk alleles for risk stratification.
• To explore potential adjustments in treatment based on identified genetic profiles.

Main Methods:

• Review of accumulated data on clopidogrel efficacy and interpatient variability.
• Identification of key enzymes (CYP2C19, P-glycoprotein) and their population allele frequencies.
• Analysis of the clinical impact of specific alleles on clopidogrel metabolism and function.

Main Results:

• Frequent CYP2C19 and P-glycoprotein alleles significantly impact clopidogrel's active metabolite formation.
• These genetic variations contribute to clinically significant interpatient variability in drug response.
• Methods exist to identify patients carrying these high-risk alleles.

Conclusions:

• CYP2C19 and P-glycoprotein genetic variability is a major contributor to clopidogrel response variability.
• The necessity and sufficiency of genetic information for risk stratification require further determination.
• Optimal treatment adjustments for patients with high-risk alleles remain unclear and warrant further investigation.